Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.64 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PNLIP | P16233 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26360106 | 0.90 | SCN8A (0.65) | SCN8ASCN10ANPC1MAPTHPGD | |
| SCHEMBL21130032 | 0.89 | SCN8A (0.71) | SCN8ASCN10ANPC1MAPTHPGD | |
| SCHEMBL23099955 | 0.89 | SCN8A (0.50) | SCN8ASCN10APNLIP | |
| SCHEMBL24925343 | 0.85 | SCN8A (0.63) | SCN8ASCN10A | |
| SCHEMBL15561702 | 0.82 | SCN8A (0.68) | SCN8ASCN10A | |
| SCHEMBL27404503 | 0.82 | PNLIP (0.52) | SCN8ASCN10APNLIP | |
| SCHEMBL16408392 | 0.81 | SCN8A (0.64) | SCN8ASCN10A | |
| SCHEMBL30530136 | 0.81 | SCN8A (0.66) | SCN8ASCN10ANPC1MAPTHPGD | |
| SCHEMBL20644052 | 0.81 | SCN8A (0.66) | SCN8ASCN10ANPC1MAPTHPGD | |
| SCHEMBL25375191 | 0.79 | SCN8A (0.64) | SCN8ASCN10ANPC1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303495-A9 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303495-A9 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SCN11A, HCN4, CACNA1F | SCN8A 18/4885SCN10A 57/4885NPC1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.